8-K: Silexion Regains Nasdaq Compliance, Avoids Delisting

Silexion Therapeutics Corp. announced it has regained full compliance with Nasdaq's minimum bid price and shareholders' equity listing requirements.

Summary

• Nasdaq confirmed Silexion Therapeutics Corp. is in compliance with Listing Rule 5550(b)(1) (Equity Requirement) and 5550(a)(2) (Minimum Bid Price Requirement) as of September 23, 2025.
• The company's shareholders' equity increased by $10.3 million through financing transactions, reaching approximately $9.41 million as of September 15, 2025, exceeding the $2.5 million requirement.
• A 1-for-15 reverse share split was effected on July 29, 2025, following shareholder approval on July 14, 2025, successfully addressing the minimum bid price deficiency.
• The company will be subject to a mandatory Nasdaq panel monitor until September 23, 2026.

Sentiment

Score: 7

Explanation: The company successfully resolved significant listing compliance issues, which is a positive step. However, the need for a reverse stock split and the ongoing monitoring period with stricter delisting rules temper the overall sentiment, indicating past challenges and future vigilance required.

Positives

• Regained full compliance with Nasdaq listing requirements, thereby avoiding delisting.
• Successfully increased shareholders' equity to approximately $9.41 million, significantly above the $2.5 million minimum required.
• Successfully addressed the minimum bid price requirement through a reverse stock split, maintaining a share price above $1.00.
• Secured continued listing on The Nasdaq Capital Market, preserving access to public capital markets.

Negatives

• The company previously failed to meet Nasdaq's Equity and Minimum Bid Price requirements, indicating past financial or market challenges.
• A reverse stock split was necessary to meet the minimum bid price, which can sometimes be viewed negatively by investors.
• The company is subject to a mandatory panel monitor until September 23, 2026, with stricter consequences for future non-compliance with the Equity Requirement.

Risks

• Failure to maintain the Equity Requirement during the one-year monitoring period (until September 23, 2026) would result in immediate delisting proceedings without the opportunity for a compliance plan or cure period.
• Potential for future non-compliance with other Nasdaq listing rules, despite current compliance.

Future Outlook

The company will be under a mandatory Nasdaq panel monitor until September 23, 2026. During this period, if the company falls out of compliance with the Equity Requirement again, it will face immediate delisting proceedings without the usual opportunity to submit a compliance plan or receive additional time.

Management Comments

• Silexion Therapeutics Corp. has demonstrated compliance with both Nasdaq Listing Rule 5550(b)(1) and Nasdaq Listing Rule 5550(a)(2).

Industry Context

na

Stakeholder Impact

• Shareholders: Avoided delisting, preserving liquidity and investment value on Nasdaq. The reverse stock split reduced the number of outstanding shares.
• Company: Maintained access to public capital markets and enhanced corporate credibility.
• Employees: Stability in the company's public listing status.

Next Steps

• Maintain compliance with Nasdaq listing rules, especially the Equity Requirement, during the one-year monitoring period.
• Operate under mandatory Nasdaq panel monitoring until September 23, 2026.

Key Dates

Recommendation

While regaining Nasdaq compliance is a crucial positive, it primarily resolves a significant risk rather than indicating new growth or operational improvements. The need for a reverse stock split and the strict monitoring period suggest underlying challenges. Investors should hold to observe sustained operational performance and financial health beyond merely meeting listing requirements before considering further investment.

Keywords

Silexion Therapeutics, SLXN, Nasdaq, Listing Compliance, Reverse Stock Split, Shareholders Equity, Minimum Bid Price, SEC Filing, 8-K